Figs (FIGS) Valuation Check As Crocs Partnership Giveaway Puts Healthcare Brand In The Spotlight
The new National Nurses Week giveaway, pairing FIGS (FIGS) with Crocs for free scrubs and clogs, puts fresh attention on FIGS’s connection to healthcare workers at a time of solid reported business performance.
See our latest analysis for FIGS.
At a share price of $14.66, FIGS has recently seen a 30 day share price return of around a 14% decline, even after a strong 90 day share price return of 28.71% and a very large 1 year total shareholder return of 269.27%. Momentum has cooled in the short term but remains notable over a longer window as investors reassess growth prospects and risk after a period of rapid gains.
If this kind of healthcare focused story interests you, it can be useful to compare FIGS with other names benefiting from similar trends by checking out 36 healthcare AI stocks
With FIGS trading at $14.66 and sitting below the average analyst price target, yet coming off very strong 1-year and 3-year total returns, investors may wonder whether there is still upside potential or if future growth is already fully reflected in the current share price.
Most Popular Narrative: 103.3% Overvalued
According to the widely followed FIGS narrative from julio, the fair value estimate of around $7.21 sits well below the recent $14.66 share price, setting up a valuation story built on premium healthcare branding and direct to consumer scale.
FIGS concentrates on a specific niche within the healthcare industry, medical professionals. The company sells primary apparel, as well as related products. By catering to the unique needs and preferences of this market segment, FIGS tailors its products to precisely match their requirements. This has allowed the company to develop a brand synonymous with this segment, improving its competitive positioning.
Curious how a focused brand, modest revenue growth assumptions and a premium future profit multiple combine into a fair value that is roughly half the current price? The tension between quality earnings forecasts and a low narrative fair value is where the real story starts, not where it ends.
Result: Fair Value of $7.21 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative could be knocked off course if execution slips further after past margin pressure, or if premium priced products meet pushback from budget conscious healthcare buyers.
Find out about the key risks to this FIGS narrative.
Next Steps
If this all feels mixed, take a moment to review the numbers yourself and decide how compelling the story is. Then check the 2 key rewards.
Looking for more investment ideas?
If FIGS caught your attention, do not stop here. Broaden your watchlist with a few targeted stock ideas that could sharpen your overall portfolio thinking.
- Scan for companies that combine quality, value and strong balance sheets by checking the solid balance sheet and fundamentals stocks screener (40 results).
- Hunt for mispriced opportunities that might not stay under the radar forever by reviewing the 59 high quality undervalued stocks.
- Round out your research with companies offering meaningful income potential by exploring the 13 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com